<DOC>
	<DOCNO>NCT01770535</DOCNO>
	<brief_summary>The purpose study understand difference individual way respond paclitaxel chemotherapy .</brief_summary>
	<brief_title>Oxford Ovarian Cancer Predict Chemotherapy Response 01</brief_title>
	<detailed_description>While paclitaxel effective kill cancer cell proportion patient , patient n't respond treatment . As chemotherapy , paclitaxel associate unpleasant side effect . We study try understand happen cancer cell different individual paclitaxel treatment make respond differently treatment . We hope study enable u develop method identify woman suitable form treatment . We also want understand cancer cell n't get kill paclitaxel . This information help u select treatment suit individual patient , thus improve outcome treatment avoid give treatment benefit patient .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Female â‰¥ 18 year age Newly diagnose histology confirm primary high grade serous ovarian cancer , high grade serous fallopian tube cancer primary peritoneal carcinoma . Radiological laparoscopic confirmation FIGO stage 3C 4 ovarian cancer . Radiological evidence omental peritoneal deposit accessible radiologyguided biopsy . At least one lesion CT scan measure least 2 cm maximum diameter perform past 31 day . Slightly old scan may accept discretion CI provide result consider remain clinically relevant . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 Life expectancy least 6 month . The patient willing able provide write informed consent comply protocol duration study , schedule visit examination . Acceptable haematological biochemical index</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Ovarian cancer , paclitaxel</keyword>
</DOC>